ReviewVaccines2022
The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Hepatitis B infection and immunity in migrant children and pregnant persons in Europe: a systematic review and meta-analysis.Journal of travel medicine · 2024Pooled it
- Global spatiotemporal analysis in hepatitis B third dose vaccine coverage from 1980-2023 across 204 countries and territories.Human vaccines & immunotherapeutics · 2026Article
- Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Article
- Primary Cancer Prevention Through Vaccination: Advances, Challenges, and Global Perspectives.Health science reports · 2026Article
- Hepatocellular Carcinoma Over Three Decades: from Screening Evolution to Integrated Therapeutic Strategies.Journal of cancer prevention · 2026Review
- Cancer Vaccines: Mobilizing Immunity for Targeted Cancer Therapy.Asian Pacific journal of cancer prevention : APJCP · 2026Review
- Blu-Ray-Based Quantification of CD98+ Extracellular Vesicles for Early Detection of Hepatocellular Carcinoma.Cancers · 2026Article
- Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma treated with TACE combined with systemic therapy.BMC gastroenterology · 2026Article
- Colorimetric loop-mediated isothermal amplification for the rapid and visual detection of hepatitis B virus.Scientific reports · 2026Article
- Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Examining perceptions, social, and policy factors influencing hepatitis B birth-dose vaccine uptake: a PEN-3 cultural model mixed-methods study of healthcare workers in Nigeria.Frontiers in health services · 2026Article
- Review
- Evaluation of hepatitis B vaccine effectiveness among fully vaccinated healthcare workers in Ethiopia.BMC infectious diseases · 2025Article
- Applying principles of vaccine development to oncomicrobial vaccines.Blood advances · 2025Review
- Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025Review
- Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019.Lancet (London, England) · 2025Article
- Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines.Vaccines · 2025Review
- Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology.JHEP reports : innovation in hepatology · 2025Review
- Global burden of liver cancer attributable to drug use: trends from 1990 to 2021 and projections to 2040.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over 1.5 million preventable new hepatitis B infections continue to occur each year and there are an estimated 296 million people living with chronic hepatitis B infection worldwide, resulting in more than 820,000 deaths annually due to liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccination remains the cornerstone of public health policy to prevent HCC and a vital component of the global hepatitis B elimination response. The WHO has set a 90% vaccination target to achieve hepatitis B elimination by 2030; however, there is wide variability in reported birth dose coverage, with global coverage at only 42%. In this review, we outline the global trends in hepatitis B vaccination coverage and the impact of hepatitis B vaccination on HCC incidence and discuss the challenges and enabling factors for achieving WHO 2030 hepatitis B vaccination coverage targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.